Canaccord raised the firm’s price target on Grail (GRAL) to $75 from $43 and keeps a Buy rating on the shares. The firm said the company remains confident in their platforms and market opportunities. The company has elaborated on reasons it expects “substantially higher” PPV in PATHFINDER 2 and also elaborated on potential future modifications to MCED legislation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL:
- Craig-Hallum healthcare/pharma analysts hold analyst/industry conference call
- GRAIL Inc Signs New Headquarters Lease Agreement
- Grail Inc’s Galleri Test Faces Uncertainty Amid Regulatory Challenges and Rising Competition
- Grail Inc’s Earnings Call Highlights Growth and Optimism
- GRAIL Inc’s Promising Outlook: Buy Rating Affirmed Amid Strong Revenue Growth and Strategic Advancements